Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion
Joon Young Hur(Hanyang University Guri Hospital), Kihyun Kım(State University of New York), Chul Won Jung(Samsung Medical Center), Jin‐Oh Choi, Jun Ho Jang(Samsung Medical Center), Jang Ho Cho(Samsung Medical Center), Ga Yeon Lee(Samsung Medical Center), Sang Eun Yoon(Sungkyunkwan University), Kang-Kook Lee(Keimyung University), Jung Eun Lee(Samsung Medical Center), Byungjun Kim(Severance Hospital), Youjin Kim(Asan Medical Center), Jung‐Sun Kim(Yonsei University), Joon Young Choi(Samsung Medical Center), Ju Hong Min(Samsung Medical Center), Sehhoon Park(Samsung Medical Center), Seok Jin Kim(Samsung (South Korea)), Won-Seog Kim(Samsung Medical Center), Eun‐Seok Jeon
Cited by 1
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymers
|Journal of Controlled Release|2003|793
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
A New Strategy for Discontinuation of Dual Antiplatelet Therapy
|Journal of the American College of Cardiology|2012|643